Link to this page
National Cancer Institute Thesaurus
| Preferred Name | Sonidegib | |
| Synonyms |
Erismodegib (1,1'-Biphenyl)-3-carboxamide, N-(6-((2R,6S)-2,6-dimethyl-4-morpholinyl)-3-pyridinyl)-2- methyl-4'-(trifluoromethoxy)-, rel- Smoothened Antagonist LDE225 LDE-225 LDE225 Odomzo SONIDEGIB Sonidegib |
|
| Definitions |
An orally bioavailable small-molecule smoothened (Smo) antagonist with potential antineoplastic activity. Sonidegib selectively binds to the hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway and, so, the inhibition of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Inappropriate activation of Hh pathway signaling and uncontrolled cellular proliferation, as is observed in a variety of cancers, may be associated with mutations in the Hh-ligand cell surface receptor Smo. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C82385 |
|
| Accepted_Therapeutic_Use_For |
locally advanced basal cell carcinoma (BCC)
|
|
| CAS_Registry |
956697-53-3
|
|
| Chemical_Formula |
C26H26F3N3O3
|
|
| code |
C82385
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc
|
|
| DEFINITION |
An orally bioavailable small-molecule smoothened (Smo) antagonist with potential antineoplastic activity. Sonidegib selectively binds to the hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway and, so, the inhibition of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Inappropriate activation of Hh pathway signaling and uncontrolled cellular proliferation, as is observed in a variety of cancers, may be associated with mutations in the Hh-ligand cell surface receptor Smo.
|
|
| Display_Name |
Sonidegib
|
|
| FDA_UNII_Code |
0RLU3VTK5M
|
|
| FULL_SYN |
Erismodegib (1,1'-Biphenyl)-3-carboxamide, N-(6-((2R,6S)-2,6-dimethyl-4-morpholinyl)-3-pyridinyl)-2- methyl-4'-(trifluoromethoxy)-, rel- Smoothened Antagonist LDE225 LDE-225 LDE225 Odomzo SONIDEGIB Sonidegib
|
|
| Has_Salt_Form | ||
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Sonidegib
|
|
| Legacy Concept Name |
Oral_Smoothened_Antagonist_LDE225
|
|
| Maps_To |
Sonidegib
|
|
| NCI_Drug_Dictionary_ID |
641974
|
|
| PDQ_Closed_Trial_Search_ID |
641974
|
|
| PDQ_Open_Trial_Search_ID |
641974
|
|
| Preferred_Name |
Sonidegib
|
|
| prefixIRI |
Thesaurus:C82385
|
|
| Semantic_Type |
Pharmacologic Substance
|
|
| UMLS_CUI |
C2830069
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |